[Form 4] ResMed Inc. Insider Trading Activity
Brett Sandercock, Chief Financial Officer of ResMed Inc. (RMD), reported that 5,462 shares of ResMed common stock were issued to him on 08/15/2025 as the result of performance-based restricted stock units (RSUs) granted on 11/20/2024. The filing shows the shares were earned when the company's compensation committee certified that the performance metrics were met; the RSUs have a vesting schedule of one-third each anniversary of the grant.
Following this issuance, Mr. Sandercock beneficially owns 88,745 shares. The reported transaction lists a price of $0, reflecting the settlement of vested RSUs rather than an open-market purchase, and the Form 4 is signed and dated 08/19/2025.
Brett Sandercock, Chief Financial Officer di ResMed Inc. (RMD), ha comunicato che il 15/08/2025 gli sono state assegnate 5.462 azioni ordinarie ResMed a seguito di unit脿 azionarie vincolate (RSU) basate sulle performance, concesse il 20/11/2024. La comunicazione indica che le azioni sono state maturate dopo la certificazione del comitato retribuzioni sull'avvenuto raggiungimento degli obiettivi di performance; le RSU seguono un piano di maturazione pari a un terzo ogni anniversario della data di concessione.
Dopo questa assegnazione, il sig. Sandercock detiene beneficiariamente 88.745 azioni. L'operazione 猫 riportata con prezzo pari a $0, a indicare il regolamento di RSU maturate e non un acquisto sul mercato, e il modulo Form 4 猫 firmato e datato 19/08/2025.
Brett Sandercock, Director Financiero de ResMed Inc. (RMD), inform贸 que el 15/08/2025 se le adjudicaron 5.462 acciones ordinarias de ResMed como resultado de unidades de acciones restringidas (RSU) basadas en rendimiento, otorgadas el 20/11/2024. El registro indica que las acciones se ganaron tras la certificaci贸n del comit茅 de compensaci贸n de que se cumplieron los criterios de rendimiento; las RSU se consolidan en un tercio en cada aniversario de la concesi贸n.
Tras esta adjudicaci贸n, el Sr. Sandercock posee beneficiariamente 88.745 acciones. La transacci贸n se reporta con un precio de $0, lo que refleja la liquidaci贸n de RSU ya consolidadas y no una compra en mercado abierto, y el Formulario 4 est谩 firmado y fechado el 19/08/2025.
ResMed Inc.(RMD)鞚� 斓滉碃鞛毂呾瀯鞛� Brett Sandercock電� 2025雲� 8鞗� 15鞚检棎 2024雲� 11鞗� 20鞚检棎 攵�鞐悳 靹标臣旮半皹 鞝滍暅欤�(RSU)搿� 鞚疙暣 ResMed 氤错喌欤� 5,462欤缄皜 攴胳棎瓴� 氚滍枆霅橃棃雼り碃 氤搓碃頄堨姷雼堧嫟. 鞁犼碃靹滌棎電� 氤挫垬鞙勳洂須岅皜 靹标臣 歆�響� 於╈”鞚� 鞚胳頃棎 霐半澕 欤检嫕鞚� 旆摑霅橃棃鞙茧┌, RSU電� 攵�鞐澕 旮办 毵る厔 1/3鞌� 氩犾姢韺呺悩電� 鞚检爼鞚措澕瓿� 鞝來榾 鞛堨姷雼堧嫟.
鞚措矆 氚滍枆 頉� Sandercock 鞌姅 鞁れ鞝侅溂搿� 88,745欤茧ゼ 氤挫湢頃橁矊 霅橃棃鞀惦媹雼�. 氤搓碃霅� 瓯半灅 臧�瓴╈潃 $0搿� 旮办灛霅橃柎 鞛堧姅雿�, 鞚措姅 瓿店皽鞁滌灔 毵れ垬 雽�鞁� 氩犾姢韺呺悳 RSU鞚� 鞝曥偘鞚� 鞚橂頃橂┌ Form 4電� 2025雲� 8鞗� 19鞚检棎 靹滊獏 氚� 旮办灛霅橃棃鞀惦媹雼�.
Brett Sandercock, directeur financier de ResMed Inc. (RMD), a d茅clar茅 que 5 462 actions ordinaires ResMed lui ont 茅t茅 attribu茅es le 15/08/2025 脿 la suite d'unit茅s d'actions restreintes (RSU) conditionn茅es 脿 la performance, accord茅es le 20/11/2024. le dossier indique que les actions ont 茅t茅 acquises apr猫s que le comit茅 des r茅mun茅rations a certifi茅 l'atteinte des objectifs de performance ; les RSU acquerront un tiers 脿 chaque anniversaire de la date d'attribution.
脌 la suite de cette attribution, M. Sandercock d茅tient 脿 titre b茅n茅ficiaire 88 745 actions. La transaction d茅clar茅e indique un prix de 0 $, refl茅tant la liquidation de RSU acquises plut么t qu'un achat sur le march茅 ouvert, et le formulaire 4 est sign茅 et dat茅 du 19/08/2025.
Brett Sandercock, Chief Financial Officer von ResMed Inc. (RMD), meldete, dass ihm am 15.08.2025 infolge leistungsabh盲ngiger Restricted Stock Units (RSUs), die am 20.11.2024 gew盲hrt wurden, 5.462 Stammaktien von ResMed zugeteilt wurden. Die Einreichung weist darauf hin, dass die Aktien zugeteilt wurden, nachdem das Verg眉tungskomitee die Erf眉llung der Leistungsziele best盲tigt hatte; die RSUs vesten zu je einem Drittel an jedem Jahrestag der Gew盲hrung.
Nach dieser Zuteilung besitzt Herr Sandercock wirtschaftlich 88.745 Aktien. Die gemeldete Transaktion weist einen Preis von $0 aus, was die Abwicklung bereits vesteter RSUs und keinen Kauf am offenen Markt widerspiegelt, und das Formular 4 ist vom 19.08.2025 unterschrieben und datiert.
- None.
- None.
Insights
TL;DR: Routine executive compensation vesting realized 5,462 shares following certified performance metrics, modestly increasing insider stake.
This Form 4 documents the settlement of performance-based RSUs into 5,462 ResMed shares for the CFO after metrics were certified. Such settlements are common compensation outcomes and do not reflect market trading intent. The incremental change in beneficial ownership (to 88,745 shares) is notable for disclosure but is unlikely by itself to materially affect valuation or share supply. Investors should view this as alignment of management pay with pre-set targets, not a directional trading signal.
TL;DR: Governance process followed: performance targets certified and RSUs vested under a scheduled plan.
The filing indicates that the compensation committee certified achievement of performance conditions tied to RSUs granted on 11/20/2024, triggering vesting on 08/15/2025. The one-third annual vesting schedule implies multi-year retention incentives. This demonstrates standard governance practice of linking pay to performance and using staggered vesting to promote retention. The disclosure is timely and file-signed on 08/19/2025, meeting Section 16 reporting expectations.
Brett Sandercock, Chief Financial Officer di ResMed Inc. (RMD), ha comunicato che il 15/08/2025 gli sono state assegnate 5.462 azioni ordinarie ResMed a seguito di unit脿 azionarie vincolate (RSU) basate sulle performance, concesse il 20/11/2024. La comunicazione indica che le azioni sono state maturate dopo la certificazione del comitato retribuzioni sull'avvenuto raggiungimento degli obiettivi di performance; le RSU seguono un piano di maturazione pari a un terzo ogni anniversario della data di concessione.
Dopo questa assegnazione, il sig. Sandercock detiene beneficiariamente 88.745 azioni. L'operazione 猫 riportata con prezzo pari a $0, a indicare il regolamento di RSU maturate e non un acquisto sul mercato, e il modulo Form 4 猫 firmato e datato 19/08/2025.
Brett Sandercock, Director Financiero de ResMed Inc. (RMD), inform贸 que el 15/08/2025 se le adjudicaron 5.462 acciones ordinarias de ResMed como resultado de unidades de acciones restringidas (RSU) basadas en rendimiento, otorgadas el 20/11/2024. El registro indica que las acciones se ganaron tras la certificaci贸n del comit茅 de compensaci贸n de que se cumplieron los criterios de rendimiento; las RSU se consolidan en un tercio en cada aniversario de la concesi贸n.
Tras esta adjudicaci贸n, el Sr. Sandercock posee beneficiariamente 88.745 acciones. La transacci贸n se reporta con un precio de $0, lo que refleja la liquidaci贸n de RSU ya consolidadas y no una compra en mercado abierto, y el Formulario 4 est谩 firmado y fechado el 19/08/2025.
ResMed Inc.(RMD)鞚� 斓滉碃鞛毂呾瀯鞛� Brett Sandercock電� 2025雲� 8鞗� 15鞚检棎 2024雲� 11鞗� 20鞚检棎 攵�鞐悳 靹标臣旮半皹 鞝滍暅欤�(RSU)搿� 鞚疙暣 ResMed 氤错喌欤� 5,462欤缄皜 攴胳棎瓴� 氚滍枆霅橃棃雼り碃 氤搓碃頄堨姷雼堧嫟. 鞁犼碃靹滌棎電� 氤挫垬鞙勳洂須岅皜 靹标臣 歆�響� 於╈”鞚� 鞚胳頃棎 霐半澕 欤检嫕鞚� 旆摑霅橃棃鞙茧┌, RSU電� 攵�鞐澕 旮办 毵る厔 1/3鞌� 氩犾姢韺呺悩電� 鞚检爼鞚措澕瓿� 鞝來榾 鞛堨姷雼堧嫟.
鞚措矆 氚滍枆 頉� Sandercock 鞌姅 鞁れ鞝侅溂搿� 88,745欤茧ゼ 氤挫湢頃橁矊 霅橃棃鞀惦媹雼�. 氤搓碃霅� 瓯半灅 臧�瓴╈潃 $0搿� 旮办灛霅橃柎 鞛堧姅雿�, 鞚措姅 瓿店皽鞁滌灔 毵れ垬 雽�鞁� 氩犾姢韺呺悳 RSU鞚� 鞝曥偘鞚� 鞚橂頃橂┌ Form 4電� 2025雲� 8鞗� 19鞚检棎 靹滊獏 氚� 旮办灛霅橃棃鞀惦媹雼�.
Brett Sandercock, directeur financier de ResMed Inc. (RMD), a d茅clar茅 que 5 462 actions ordinaires ResMed lui ont 茅t茅 attribu茅es le 15/08/2025 脿 la suite d'unit茅s d'actions restreintes (RSU) conditionn茅es 脿 la performance, accord茅es le 20/11/2024. le dossier indique que les actions ont 茅t茅 acquises apr猫s que le comit茅 des r茅mun茅rations a certifi茅 l'atteinte des objectifs de performance ; les RSU acquerront un tiers 脿 chaque anniversaire de la date d'attribution.
脌 la suite de cette attribution, M. Sandercock d茅tient 脿 titre b茅n茅ficiaire 88 745 actions. La transaction d茅clar茅e indique un prix de 0 $, refl茅tant la liquidation de RSU acquises plut么t qu'un achat sur le march茅 ouvert, et le formulaire 4 est sign茅 et dat茅 du 19/08/2025.
Brett Sandercock, Chief Financial Officer von ResMed Inc. (RMD), meldete, dass ihm am 15.08.2025 infolge leistungsabh盲ngiger Restricted Stock Units (RSUs), die am 20.11.2024 gew盲hrt wurden, 5.462 Stammaktien von ResMed zugeteilt wurden. Die Einreichung weist darauf hin, dass die Aktien zugeteilt wurden, nachdem das Verg眉tungskomitee die Erf眉llung der Leistungsziele best盲tigt hatte; die RSUs vesten zu je einem Drittel an jedem Jahrestag der Gew盲hrung.
Nach dieser Zuteilung besitzt Herr Sandercock wirtschaftlich 88.745 Aktien. Die gemeldete Transaktion weist einen Preis von $0 aus, was die Abwicklung bereits vesteter RSUs und keinen Kauf am offenen Markt widerspiegelt, und das Formular 4 ist vom 19.08.2025 unterschrieben und datiert.
